Commonwealth Equity Services LLC reduced its stake in Regeneron Pharmaceuticals by 5.1% in Q4, selling 967 shares and ...

The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.

Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.